208 companies · NSE & BSE · Updated daily
The Indian pharmaceutical sector, a consistent performer, is showing signs of renewed strength. Driven by domestic demand, export opportunities, and a focus on specialty generics, many Indian pharma players are poised for growth. Bull Run's analysis highlights stocks exhibiting robust financial health and promising valuations.
Indian pharmaceutical companies are increasingly leveraging their R&D capabilities and manufacturing prowess to capture global market share, particularly in regulated markets like the US. Favorable regulatory pathways, such as USFDA approvals and ANDA filings, are critical indicators of future revenue streams. While the sector grapples with pricing pressures in certain segments, a strategic shift towards complex generics and contract development and manufacturing (CDMO) services is proving effective. Diversification across therapeutic areas and geographies mitigates risk and enhances long-term sustainability.
What to Watch
Monitor USFDA inspection outcomes and the pace of new product approvals. Keep an eye on the evolving regulatory landscape in key export markets and the competitive intensity in the domestic formulations business. Increasing R&D spends and CDMO order books are positive signals for future growth.
What are the key drivers for the Indian Pharma sector's bull run?
Key drivers include strong domestic demand, increasing export opportunities in regulated markets, government initiatives like PLI schemes, and a growing focus on specialty and complex generics. The CDMO segment is also a significant growth catalyst.
How important are USFDA approvals for Indian pharma stocks?
USFDA approvals are crucial as they grant access to the lucrative US market, which is the largest pharmaceutical market globally. Successful approvals and inspections indicate product quality and compliance, directly impacting revenue potential and investor confidence.
What is the role of R&D and innovation in this sector?
R&D and innovation are vital for developing differentiated products, complex generics, and biosimilars. Companies investing significantly in R&D are better positioned to command higher margins and gain a competitive edge, especially in innovation-driven segments.
How does the Bull Run score assess pharma stocks?
The Bull Run score evaluates pharma stocks based on financial health (ROE, debt-to-equity), valuation metrics (P/E), and growth prospects. It aims to identify fundamentally sound companies trading at reasonable valuations within the sector.
| # | Company | Symbol | Price | Change | Market Cap |
|---|---|---|---|---|---|
| 61 | Unichem Laboratories Ltd | UNICHEMLAB | ₹449.45 | +0.69% | ₹3.2K Cr |
| 62 | Sms Pharmaceuticals Ltd | SMSPHARMA | ₹375.95 | -0.12% | ₹2.9K Cr |
| 63 | Hikal Ltd | HIKAL | ₹189.96 | +0.14% | ₹2.8K Cr |
| 64 | IOL Chemicals and Pharmaceuticals Ltd | IOLCP | ₹125.10 | -0.76% | ₹2.6K Cr |
| 65 | Indoco Remedies Ltd | INDOCO | ₹231.23 | -0.75% | ₹2.4K Cr |
| 66 | Morepen Laboratories Ltd | MOREPENLAB | ₹51.48 | -1.53% | ₹2.4K Cr |
| 67 | Solara Active Pharma Sciences Ltd | SOLARA | ₹581.45 | -1.31% | ₹2.3K Cr |
| 68 | Panacea Biotec Ltd | PANACEABIO | ₹532.20 | -2.34% | ₹2.2K Cr |
| 69 | Novartis India Ltd | NOVARTIND | ₹1365.60 | +3.18% | ₹2.0K Cr |
| 70 | Amrutanjan Health Care Ltd | AMRUTANJAN | ₹533.75 | -1.39% | ₹2.0K Cr |
| 71 | BETA Technologies, Inc Class A Common Stock | BETA | ₹1661.10 | +0.00% | ₹1.7K Cr |
| 72 | Shukra Pharmaceuticals Ltd | SHUKRAPHAR | ₹31.18 | +0.10% | ₹1.7K Cr |
| 73 | Windlas Biotech Ltd | WINDLAS | ₹817.00 | -1.47% | ₹1.7K Cr |
| 74 | Bliss GVS Pharma Ltd | BLISSGVS | ₹474.85 | +5.08% | ₹1.6K Cr |
| 75 | Syncom Formulations India Ltd | SYNCOMF | ₹14.22 | -0.97% | ₹1.5K Cr |
| 76 | Jagsonpal Pharmaceuticals Ltd | JAGSNPHARM | ₹209.19 | -0.03% | ₹1.5K Cr |
| 77 | Sigachi Industries Ltd | SIGACHI | ₹21.71 | +2.55% | ₹1.4K Cr |
| 78 | Hester Biosciences Ltd | HESTERBIO | ₹2052.60 | -0.09% | ₹1.4K Cr |
| 79 | Bajaj Healthcare Ltd | BAJAJHCARE | ₹299.20 | -1.03% | ₹1.4K Cr |
| 80 | Lincoln Pharmaceuticals Ltd | LINCOLN | ₹629.75 | -2.52% | ₹1.0K Cr |
| 81 | Venus Remedies Ltd | VENUSREM | ₹1774.50 | -5.00% | ₹1.0K Cr |
| 82 | Themis Medicare Ltd | THEMISMED | ₹102.64 | +1.12% | ₹1.0K Cr |
| 83 | Kwality Pharmaceuticals Ltd | KPL | ₹2360.80 | -2.77% | ₹1.0K Cr |
| 84 | Fredun Pharmaceuticals Ltd | FREDUN | ₹2610.15 | +3.06% | ₹0.9K Cr |
| 85 | Wanbury Ltd | WANBURY | ₹267.95 | -0.20% | ₹0.9K Cr |
| 86 | Anlon Healthcare | AHCL | ₹15.99 | -0.50% | ₹0.9K Cr |
| 87 | Sakar Healthcare Ltd | SAKAR | ₹801.40 | -2.62% | ₹0.9K Cr |
| 88 | Remus Pharmaceuticals Ltd | REMUS | ₹764.80 | +1.15% | ₹0.8K Cr |
| 89 | NGL Fine Chem Ltd | NGLFINE | ₹2930.30 | -1.56% | ₹0.8K Cr |
| 90 | ACCENTMICST | ACCENTMIC | ₹267.00 | +0.00% | ₹0.8K Cr |